We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




GSI Group Acquires Blood Processing Equipment Manufacturer GenesisBPS

By LabMedica International staff writers
Posted on 07 Oct 2025

Blood processing and storage are vital to healthcare and clinical practice, ensuring safe transfusions and cellular therapies. More...

However, hospitals and laboratories worldwide face challenges in maintaining high-quality standards while managing increasing demand for blood collection and processing. Now, a new business acquisition aims to expand global accessibility to mission-critical blood processing equipment and consumables.

GSI Group Holdings (Irvine, CA, USA) has acquired GenesisBPS (Ramsey, NJ, USA), a designer and manufacturer of specialized benchtop blood processing equipment and laboratory consumables. GenesisBPS has become the newest addition to GSI Group's growing family of benchtop equipment and single-use product brands serving the life sciences, research & development, industrial, and academia & education markets.

GSI Group provides a wide range of essential laboratory single-use products, precision benchtop instruments, and related accessories. The platform has built a global reach, with locations across the U.S., Europe, and Asia, and the business collectively serves customers in more than 100 countries. Today, thousands of leading research institutions, diagnostic laboratories, hospitals, universities, and industrial organizations depend on GSI Group products to support their daily operations. GenesisBPS joins existing GSI Group brands, including Globe Scientific, AmScope, Euromex, and Physix.

Founded in 1990, GenesisBPS has become a premier provider of mission-critical blood processing and collection instruments, consumables, and accessories. Its products are widely used in blood banks, hospitals, clinical laboratories, and cellular therapy applications where they play an essential role in ensuring the safe collection, processing, and storage of blood and other biological fluids. The addition of GenesisBPS further strengthens GSI Group's position as a leading provider of laboratory benchtop equipment and single-use products. The GSI Group platform will continue strategic acquisitions of leading brands of benchtop equipment and consumables across North America and Europe.

"We are excited to have GenesisBPS join GSI as part of the expanding global platform," said Philip Herman, Vice President of Global Sales and Marketing at GenesisBPS. "Our focus has always been on delivering innovative and high-quality solutions to customers across the blood processing and life sciences sectors. Partnering with GSI provides us with the resources, scale, and global footprint to expand our impact and support more institutions and patients worldwide."

"GenesisBPS is an outstanding strategic fit for GSI," added Jon Brubaker, CEO of GSI Group. "It's specialized equipment and consumables enhance our capabilities in critical blood processing workflows, further expanding the value we deliver to customers in the life sciences, diagnostics, and academic research fields. We remain committed to accelerating GSI's growth through both organic initiatives and additional acquisitions of leading brands."

Related Links:
GSI Group Holdings
GenesisBPS


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.